Neuroendocrine breast carcinoma metastatic to the liver: Report of a case and review of the literature

Manes, Konstantinos; Delis, Spyridon; Papaspyrou, Nikolaos; Ghiconti, Ioanna; Dervenis, Christos

doi:10.1016/j.ijscr.2014.05.006

Cited by 9 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic sites include liver, bones, lung, pancreas, softtissues, and brain [42].Whenmetastatic disease is suspected, especially in the case of metachronous metastases developed after a long latency period from the treatment of the primary tumor, a biopsy of the metastatic site would be useful to confirm the diagnosis and also to analyze the molecular characteristics of the disease, including immunohistochemistry markers of neuroendocrine differentiation, HER2, and hormone receptor status, given the possible heterogeneity between primary breast cancer and metastases [43].…”

Section: Treatmentmentioning

confidence: 99%

“…Surgical resection may represent a valid option for liver metastases in selected cases, because prolonged survival has been reported after hepatectomy [42,44]. Liver surgery should be pursued if a R0 resection is feasible and when there is no evidence of extrahepatic disease, except for bone metastases, which can be controlled by radiotherapy.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline-and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. The Oncologist 2016;21:28-32 Implications for Practice: Neuroendocrine carcinoma of the breast (NECB) is a distinct entity of breast cancer. Clinical features and morphology are not helpful to distinguish NECB from other subtypes of breast cancer; therefore, immunohistochemistry markers for neuroendocrine differentiation, mainly chromogranin and synaptophysin, should be routinely used to confirm the diagnosis, especially in cases of mucinous or solid papillary carcinoma in which the suspicion of NECB may be relevant. Adjuvant treatment should be offered according to the same recommendations given for the other types of invasive breast cancer. An accurate diagnosis of NECB is also important in the metastatic setting, in which a multimodality approach including specific therapies such as peptide receptor radionuclide therapy can be considered.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Neuroendocrine carcinoma of the breast can metastasize to multiple sites even years after the treatment for primary tumor, and therefore, a long‐term follow‐up is advisable. Metastatic sites include liver, bones, lung, pancreas, soft tissues, and brain …”

Section: Discussionmentioning

confidence: 99%

Primary neuroendocrine carcinoma of the breast: A case report of liver and lymph node metastases after eight years from diagnosis

et al. 2020

View full text Add to dashboard Cite

Primary neuroendocrine carcinoma of the breast (NECB) is one of the rarest subtypes of breast tumor, and for this reason, there are no data from prospective clinical trials on its optimal management. Its incidence is <0.1% of all breast cancers and <1% of all neuroendocrine tumors. The diagnosis of NECB requires the expression of neuroendocrine markers (chromogranin, synaptophysin, NSE) and the lack of simultaneous neuroendocrine carcinoma in extramammary sites. We present a case of a poorly differentiated neuroendocrine carcinoma (PD‐NEC) metastasized in liver and lymph node after eight years. Mammography, ultrasound imaging, CT, and pathology findings are described.

show abstract

“…NECB can metastasise to multiple sites, even many years after treatment of the primary tumour; therefore, long-term follow-up is recommended. Most often, metastases are found in the lymph nodes, liver, bones, lungs, pancreas, soft tissues, and the brain [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…Resection of a liver metastasis should be considered, if it is possible to remove it completely (R0) and there are no extrahepatic foci (with the exception of bone metastases that can be controlled by radiotherapy) [ 3 ]. According to some reports, hepatectomy may prolong the survival of patients with NECB [ 10 ]. Stereotactic radiotherapy is an alternative to surgery.…”

Section: Discussionmentioning

confidence: 99%

Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer

Struk-Panfil

Błaut

Pęksa

et al. 2018

View full text Add to dashboard Cite

We report on and discuss a case of a female patient diagnosed with breast cancer in 1996, which was histopathologically assessed as an invasive ductal carcinoma. The patient was admitted to our Department in 2017 with a liver metastasis of a neuroendocrine tumour. On admission she had no symptoms of an endo-crinopathy and was in a good general condition. Due to unknown primary site of the metastasis and given the patient’s history of breast cancer, it was suspected that the breast cancer was in fact a neuroendocrine tumour. This hypothesis was confirmed by comparing histopathological specimens of the breast and liver tumours using advanced pathological methods.

show abstract

Neuroendocrine breast carcinoma metastatic to the liver: Report of a case and review of the literature

Cited by 9 publications

References 22 publications

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Primary neuroendocrine carcinoma of the breast: A case report of liver and lymph node metastases after eight years from diagnosis

Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer

Contact Info

Product

Resources

About